Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy (ExCell)
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Sponsor: Gamida Cell -Teva Joint Venture Ltd.
A PHASE2/PHASE3 clinical study on Acute Myeloid Leukemia and Chronic Myeloid Leukemia, this trial is completed. The trial is conducted by Gamida Cell -Teva Joint Venture Ltd. and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gamida Cell -Teva Joint Venture Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aurora, United States , Av Campanar 21, Valencia, Spain , Avda. Blasco Ibañez, 17, Valencia, Spain , Budapest, Hungary , C/ Sant Antoni Maria Claret, Barselona, Spain , Carretera de Canyet S/n, Badalona, Spain , Chicago, United States , Cleveland, United States , Doctor Esquerdo 46 , Madrid, Spain , Hackensack, United States and 16 more locations